Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly carfilzomib + daratumumab + lenalidomide + dexamethasone for transplant-ineligible bortezomib-induction nonresponsive multiple myeloma
MOH_2018-01-18_001958Phase 2Completed
- Sponsor
- דר' יעל כהן
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of carfilzomib, daratumumab, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by דר' יעל כהן. Primary endpoints: Safety, Tolerability and 1 more. Started Aug 2017; status: completed.
02
Drugs
carfilzomibdaratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2018-01-18_001958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-01-18_001958.